RS50471B - N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih sadrže - Google Patents

N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih sadrže

Info

Publication number
RS50471B
RS50471B YUP-297/02A YUP29702A RS50471B RS 50471 B RS50471 B RS 50471B YU P29702 A YUP29702 A YU P29702A RS 50471 B RS50471 B RS 50471B
Authority
RS
Serbia
Prior art keywords
groups
formula
group
alkyl
substituted
Prior art date
Application number
YUP-297/02A
Other languages
English (en)
Serbian (sr)
Inventor
Otmar Klingler
Gerhard Zoller
Elisabeth Defossa
Fahad Al-Obeidi
Armin Walser
James Ostrem
Original Assignee
Sanofi-Aventis Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh. filed Critical Sanofi-Aventis Deutschland Gmbh.
Priority to MEP-547/08A priority Critical patent/MEP54708A/xx
Publication of YU29702A publication Critical patent/YU29702A/sh
Publication of RS50471B publication Critical patent/RS50471B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
YUP-297/02A 1999-10-30 2000-10-21 N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih sadrže RS50471B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-547/08A MEP54708A (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99121623A EP1095933A1 (en) 1999-10-30 1999-10-30 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (2)

Publication Number Publication Date
YU29702A YU29702A (sh) 2005-06-10
RS50471B true RS50471B (sr) 2010-03-02

Family

ID=8239305

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-297/02A RS50471B (sr) 1999-10-30 2000-10-21 N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih sadrže

Country Status (31)

Country Link
US (2) US6472562B1 (https=)
EP (2) EP1095933A1 (https=)
JP (1) JP4658430B2 (https=)
KR (1) KR100981593B1 (https=)
CN (1) CN1249026C (https=)
AR (1) AR026257A1 (https=)
AT (1) ATE264837T1 (https=)
AU (1) AU776797B2 (https=)
BR (1) BR0015186A (https=)
CA (1) CA2389412C (https=)
CZ (1) CZ301855B6 (https=)
DE (1) DE60010113T2 (https=)
DK (1) DK1228039T3 (https=)
EE (1) EE05168B1 (https=)
ES (1) ES2220553T3 (https=)
HR (1) HRP20020372B1 (https=)
HU (1) HUP0203627A3 (https=)
IL (2) IL149209A0 (https=)
ME (1) MEP54708A (https=)
MX (1) MXPA02003805A (https=)
NO (1) NO328016B1 (https=)
NZ (1) NZ518607A (https=)
PL (1) PL203859B1 (https=)
PT (1) PT1228039E (https=)
RS (1) RS50471B (https=)
RU (1) RU2253651C2 (https=)
SI (1) SI1228039T1 (https=)
SK (1) SK286856B6 (https=)
TR (1) TR200201181T2 (https=)
WO (1) WO2001032611A1 (https=)
ZA (1) ZA200203294B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579240B2 (ja) * 2003-07-04 2010-11-10 ロンザ アーゲー 担持相合成法の改善
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
RU2377990C1 (ru) * 2008-07-23 2010-01-10 Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
PT2453910T (pt) 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
CN110357800B (zh) * 2018-04-09 2022-07-26 青岛海生洋润生物科技有限公司 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN115317474A (zh) * 2021-05-10 2022-11-11 中国海洋大学 一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU206372B (en) * 1990-09-03 1992-10-28 Richter Gedeon Vegyeszet Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH08506225A (ja) 1993-01-20 1996-07-02 ジョン アリグザンドロビクス，ピーター ラインモニタシステム
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
SI9520044B (sl) 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
DE69529770T2 (de) * 1994-12-02 2003-12-24 Yamanouchi Pharmaceutical Co., Ltd. Neues amidinonaphthylderivat oder dessen salz
US6342504B1 (en) * 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
EP1020434A4 (en) * 1997-08-27 2000-11-15 Kissei Pharmaceutical 3-AMIDINOANILINE DERIVATIVES, INHIBITORS OF THE ACTIVATED BLOOD COINTENANCE FACTOR X AND INTERMEDIATE PRODUCTS FOR PRODUCING BOTH
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
HU227568B1 (en) 1997-12-24 2011-08-29 Sanofi Aventis Deutschland Indole derivatives, as inhibitors os factor xa
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
ES2226839T3 (es) * 1999-05-05 2005-04-01 MERCK & CO., INC. Nuevos catecoles como agentes antimicrobianos.

Also Published As

Publication number Publication date
MEP54708A (en) 2011-05-10
SK286856B6 (sk) 2009-06-05
CN1387508A (zh) 2002-12-25
MXPA02003805A (es) 2004-10-15
HRP20020372A2 (en) 2004-08-31
EE200200199A (et) 2003-06-16
EP1095933A1 (en) 2001-05-02
US6472562B1 (en) 2002-10-29
RU2002114041A (ru) 2004-01-20
PT1228039E (pt) 2004-09-30
EP1228039B1 (en) 2004-04-21
KR100981593B1 (ko) 2010-09-13
JP2003513066A (ja) 2003-04-08
PL203859B1 (pl) 2009-11-30
NZ518607A (en) 2003-10-31
SK5782002A3 (en) 2002-10-08
AU1026501A (en) 2001-05-14
HRP20020372B1 (hr) 2011-01-31
ZA200203294B (en) 2003-01-29
CA2389412C (en) 2009-12-01
ES2220553T3 (es) 2004-12-16
ATE264837T1 (de) 2004-05-15
RU2253651C2 (ru) 2005-06-10
CZ301855B6 (cs) 2010-07-14
DE60010113T2 (de) 2005-05-04
SI1228039T1 (en) 2004-10-31
DK1228039T3 (da) 2004-08-16
CA2389412A1 (en) 2001-05-10
WO2001032611A1 (en) 2001-05-10
US20030162967A1 (en) 2003-08-28
KR20020047310A (ko) 2002-06-21
EE05168B1 (et) 2009-06-15
DE60010113D1 (de) 2004-05-27
CN1249026C (zh) 2006-04-05
AU776797B2 (en) 2004-09-23
NO20022022D0 (no) 2002-04-29
BR0015186A (pt) 2002-07-23
IL149209A (en) 2007-06-03
HUP0203627A3 (en) 2004-12-28
EP1228039A1 (en) 2002-08-07
JP4658430B2 (ja) 2011-03-23
CZ20021489A3 (cs) 2002-07-17
IL149209A0 (en) 2002-11-10
HK1050673A1 (en) 2003-07-04
HUP0203627A2 (hu) 2003-03-28
PL354808A1 (en) 2004-02-23
NO328016B1 (no) 2009-11-09
TR200201181T2 (tr) 2002-09-23
US6664393B2 (en) 2003-12-16
AR026257A1 (es) 2003-02-05
YU29702A (sh) 2005-06-10
NO20022022L (no) 2002-04-29

Similar Documents

Publication Publication Date Title
RU2286337C2 (ru) ПРОИЗВОДНЫЕ (ТИО)МОЧЕВИНЫ, ИНГИБИРУЮЩИЕ ФАКТОР VIIa, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
AU776797B2 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
US20020173656A1 (en) Guanidine and amidine derivatives as factor Xa inhibitors
AU2002233206A1 (en) Guanidine and amidine derivatives as factor xa inhibitors
JP2004530726A (ja) 抗蛋白分解活性を有する尿素誘導体
JP4546683B2 (ja) ファクターＶＩＩａ阻害剤
JP5016178B2 (ja) 抗血栓活性を有するマロンアミドおよびマロンアミド酸エステル誘導体、それらの製造および使用